Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

34.41 -0.02 (-0.04%)
Delayed Quote Updated: 10:01 AM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Harmony Biosciences (HRMY) Q3 2026 Earnings Call Transcript ↗
CEO succession and BP-205 early data shape the quarter's outlook. 
Via The Motley Fool
Topics Earnings
News headline image
Harmony Biosciences Q3 Earnings Call Highlights ↗
Harmony Biosciences (NASDAQ:HRMY) reported third-quarter net revenue of $269 million, up from $239 million a year earlier, as demand for its narcolepsy treatment WAKIX continued to grow. The company... 
Via MarketBeat
Topics Earnings Economy Intellectual Property
Harmony Biosciences Holdings (NASDAQ:HRMY) Q3 2026 Earnings Miss Overshadows WAKIX Growth ↗
Via Chartmill
Topics Earnings
News headline image
Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
From Harmony Biosciences
Via GlobeNewswire
Harmony Biosciences Holdings (NASDAQ:HRMY): A Value Stock with Strong Financial Health ↗
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Q1 Revenue Meets Guidance, But EPS Miss and Elevated Spending Weigh on Shares ↗
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY): A Decent Value Play with Strong Fundamentals ↗
Via Chartmill
News headline image
4 Small-Cap Stocks With Paths to Recovery After the Fed's September Rate Hike ↗
Amid a Russell 2000 sell-off driven by rising rates, FIBK, EPAC, CCS, and HRMY show varied resilience, with analysts weighing risks against potential upside in each stock. 
Via MarketBeat
Topics Economy
News headline image
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
From Harmony Biosciences
Via GlobeNewswire
News headline image
Why Harmony Biosciences Stock Got Mashed on Monday ↗
Investors weren't cheered by a major change in the company's leadership. 
Via The Motley Fool
News headline image
Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
From Harmony Biosciences
Via GlobeNewswire
News headline image
Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
From Harmony Biosciences
Via GlobeNewswire
News headline image
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
From Harmony Biosciences
Via GlobeNewswire
News headline image
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
From Harmony Biosciences
Via GlobeNewswire
News headline image
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline ↗
Harmony Biosciences (NASDAQ:HRMY) highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant... 
Via MarketBeat
News headline image
Harmony Biosciences (HRMY) Q2 2026 Earnings Call Transcript ↗
WAKIX revenue surged 30% to $261.3 million, confirming $1 billion annual guidance. 
Via The Motley Fool
Topics Earnings
News headline image
Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium
From Harmony Biosciences
Via GlobeNewswire
News headline image
Harmony Biosciences Q2 Earnings Call Highlights ↗
Harmony Biosciences (NASDAQ:HRMY) reported second-quarter net revenue of $261.3 million, up 30% from the prior-year period and 21% sequentially, as sales of its narcolepsy treatment WAKIX rebounded... 
Via MarketBeat
Topics Earnings
News headline image
Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
From Harmony Biosciences
Via GlobeNewswire
News headline image
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
From Harmony Biosciences
Via GlobeNewswire
News headline image
Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony (HRMY) Q1 2026 Earnings Transcript ↗
Harmony (HRMY) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
News headline image
Harmony Biosciences to Participate in Upcoming Investor Conferences
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
A Healthcare Fund Just Made Bitgo Its Biggest Bet ↗
Bitgo Holdings provides digital asset infrastructure and custody services for institutional clients, supporting secure management at scale. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
A beaten-down biotech just lost a meaningful backer — should you care? ↗
Harmony Biosciences develops therapies for rare neurological disorders, with WAKIX addressing excessive sleepiness in narcolepsy patients. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer
From Harmony Biosciences Holdings, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.